Today: 21 May 2026
Ford stock price today: F shares edge up as lawmaker probes CATL battery plans ahead of earnings
29 January 2026
2 mins read

Ford stock price today: F shares edge up as lawmaker probes CATL battery plans ahead of earnings

New York, Jan 29, 2026, 11:28 EST — Regular session

  • Ford shares ticked up roughly 0.5%, reaching $13.90 in late morning trading.
  • A U.S. lawmaker challenged Ford over its battery plans tied to CATL and whether they qualify for tax credits.
  • Investors are eyeing Ford’s Feb. 10 quarterly update for clues on its battery and energy-storage strategy.

Ford Motor shares edged up 0.5% to $13.90 in late morning New York trading on Thursday, finding footing after a flurry of Washington scrutiny over its China-related battery strategy. The stock fluctuated between $13.80 and $13.98.

The scrutiny is crucial as Ford aims to establish U.S. supply chains for lithium iron phosphate, or LFP, cells—a cheaper battery type that could bring down costs for mass-market EVs. It also affects tax credits that reduce sticker prices for consumers and influence automakers’ margins.

Representative John Moolenaar, the Republican chair of a House committee on China, pressed CEO Jim Farley about Ford’s licensing deal with China’s CATL and whether it might impact eligibility for new U.S. tax credits. Ford plans to build a $3 billion LFP battery plant in Marshall, Michigan, kicking off production this year. That facility is set to supply batteries for a $30,000 midsize EV truck in the works. The company expressed confidence its batteries comply with tax-credit requirements, emphasizing that “expanding LFP battery production here in the United States isn’t just an investment in energy security — it’s an investment in American workers.” Reuters

Ford is making a bigger push into grid batteries. This week, it appointed Lisa Drake as president of Ford Energy to spearhead battery energy storage systems—large-scale packs designed to store electricity for utilities and major energy consumers. She will report to Vice Chair John Lawler. “Lisa has deep expertise in scaling complex industrial systems,” Lawler said. Drake added, “Ford Energy allows us to maximize the value of our battery manufacturing capabilities.” Ford From the Road

Ford plans to introduce a new lithium iron phosphate (LFP) battery and a boosted motor for the Standard Range versions of its all-electric Explorer SUV and Capri crossover in Europe. This upgrade pushes the driving range past 440 km. Jon Williams, general manager for Ford Blue and Model e in Europe, said, “By upgrading the Explorer and Capri with new LFP battery technology, we are increasing range and durability while keeping it affordable for our customers.” Ford From the Road

Ford is recalling close to 117,000 U.S. vehicles equipped with an aftermarket engine block heater. The heaters have a risk of cracking, leaking coolant, and short-circuiting when plugged in, which could lead to fires, according to WardsAuto. The company plans to send interim letters starting Feb. 9, with remedy notices following on April 13, the report added.

General Motors climbed 1.1%, but Tesla dropped 2.1%.

The market remains uncertain about the Federal Reserve’s next move on rate cuts after the central bank paused on Wednesday without clear hints on timing. For automakers, this matters—since most U.S. buyers rely on financing to make their purchases.

But there’s risk on the horizon. Should policymakers clamp down on Chinese-linked battery supply, Ford might see delays, increased costs, or lose access to key incentives. On top of that, widespread recall repairs could squeeze margins further.

Ford’s next big moment comes on Feb. 10, when it holds its fourth-quarter 2025 earnings call at 5 p.m. ET. Investors will be watching for updates on the Marshall battery plant, the rollout of Ford Energy, and any shifts in warranty trends.

Stock Market Today

  • Nanobiotix Halts Trading on Euronext Paris Ahead of Global Offering Pricing
    May 21, 2026, 3:15 AM EDT. Nanobiotix, a late-stage biotechnology firm specializing in physics-based cancer treatments, has temporarily halted trading of its ordinary shares on Euronext Paris at its own request. The halt, effective from market open on May 21, 2026, is linked to its global offering, consisting of a U.S. public offering of American Depositary Shares and an international offering of ordinary shares and pre-funded warrants to qualified European investors. Trading is expected to resume later the same day after allocation confirmations and pricing announcements. Nanobiotix, listed on Euronext and Nasdaq, holds over 25 patent families covering nanotechnology platforms in oncology, bioavailability, and central nervous system disorders.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Dow Jones today: DJIA edges up near 49,000 as AI spending scrutiny deepens
Previous Story

Dow Jones today: DJIA edges up near 49,000 as AI spending scrutiny deepens

Silver price today whipsaws after record high as profit-taking bites; SLV, miners fall
Next Story

Silver price today whipsaws after record high as profit-taking bites; SLV, miners fall

Go toTop